Melarth

Montelukast, the active ingredient in Melarth, is a leukotriene receptor antagonist presented as a dosage form for buccal, cutaneous, dental and nasal use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children as prescribed.

GNH USA supplies Melarth as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is used to manage conditions mediated by leukotrienes, primarily in the respiratory and allergic disease spectrum.

- Asthma: reduces symptom frequency, improves lung function and decreases exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity.

Common Side Effects: - Headache: mild to moderate pain often transient. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional irritation of the throat. - Nausea: feeling of unease or urge to vomit. - Sore throat: irritation or pain in the throat. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Eosinophilic granulomatosis with polyangiitis: rare vasculitis. - Hepatic injury: abnormal liver function tests. - Anaphylaxis: life‑threatening allergic reaction. - Mood changes: including depression or suicidal thoughts.

Precautions should be considered before initiating therapy with Montelukast. - Liver function assessment: evaluate hepatic status, especially in patients with known liver disease. - Neuropsychiatric monitoring: watch for mood changes, depression or suicidal ideation. - Severe hepatic impairment: use with caution and adjust therapy as needed. - Hypersensitivity: avoid in individuals with known allergy to Montelukast or excipients. - Drug interactions: review concomitant medications for potential interactions. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Montelukast may interact with several medicines; clinicians should assess the risk.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition may increase Montelukast levels. - Ritonavir: potent CYP3A4 inhibitor can raise exposure. - Phenobarbital: enzyme inducer that reduces efficacy. - Carbamazepine: induces metabolism, decreasing therapeutic effect. - Rifampin: strong inducer leading to reduced plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may alter anticoagulant effect. - Theophylline: potential additive bronchodilator effect. - Beta‑agonists: monitor for enhanced bronchodilation. - NSAIDs: watch for increased gastrointestinal irritation. - Oral contraceptives: possible reduction in contraceptive efficacy.